PATENTS ON RANDOM COMPLEMENTARY-DNA FRAGMENTS
PATENTS ON RANDOM COMPLEMENTARY-DNA FRAGMENTS
复制标题
DOI：
10.1126/science.1502558
复制
发表时间：
1992-08-14
期刊：
影响因子：
56.9
通讯作者：
KILEY, TD
中科院分区：
文献类型：
--
作者：
KILEY, TD
美国国立卫生研究院（NIH）对仅仅由人类基因组测序产生的产品申请专利的提议是一个错误：最坏的情况是，它违反了专利法；在最好的情况下，它依赖于法律上关于什么是“有用的”作为专利要求的缺陷。这一提议是困扰生物技术的一个问题的征兆——试图在研究确定这些材料的实用价值之前控制科学实验的原料——这些原料需要在许多方面进行养护。纠正措施被提出供行政部门、国会和法院采纳。
The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology-attempts to control the raw material of scientific experimentation before research has determined the practical value of such material-that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.